Congress Materials – Congress of Clinical Rheumatology (CCR EAST 2026)
2026 Congress of Clinical Rheumatology | Apr 30-May 3 | Destin, FL
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
12-Month Persistence and Multi-Domain Effectiveness of Guselkumab in Adults With Active Psoriatic Arthritis: Real-World Data from the PPD CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry
Philip J. Mease, Alexis Ogdie, John Tesser, Timothy P. Fitzgerald, Elizabeth Adamson, Soumya D. Chakravarty, Robert R. McLean, Taylor S. Blachley, Melissa Eliot, Skyler S. Peterson, Aaron Broadwell, Kurt Oelke, Arthur Kavanaugh, Joseph F. Merola
This document will be available on April 30 2026
Achievement of DAPSA/cDAPSA Low Disease Activity With Guselkumab in Active and Erosive Psoriatic Arthritis Across Participant Subgroups in APEX
Christopher T Ritchlin, Laura C Coates, Philip J Mease, Alexa P Kollmeier, Weihong Hu, Soumya D Chakravarty, Stacey Fitch, Karissa Lozenski, Alexis Ogdie, Proton Rahman
This document will be available on April 30 2026
Clinically Relevant Anti-Vaccine and Virus Antibodies in Patients With Sjogren’s Disease Treated With Nipocalimab: Post-Hoc Analysis of the DAHLIAS Study
Faye Yu, Eugene Myshkin, Jonathan J. Hubbard, Kim Campbell, Matthew J. Loza, Dessislava Dimitrova, Carolyn Cuff, Sheng Gao
This document will be available on April 30 2026
Durable Inhibition of Structural Damage Progression and Improvements in Joint Disease Activity with Guselkumab in Active and Erosive Psoriatic Arthritis: Week 48 Results from APEX
Christopher T Ritchlin, Philip J Mease, Laura C Coates, Alexa P Kollmeier, Bei Zhou, Yusang Jiang, Karen Bensley, Koeun Im, Rattandeep Batra, Karissa Lozenski, Steven Fakharzadeh, Soumya D Chakravarty, Proton Rahman, Désirée van der Heijde
This document will be available on April 30 2026
Efficacy of Intravenous and Subcutaneous Guselkumab Induction by Weight and Body Mass Index in Patients with Crohn’s Disease: Phase 3 GALAXI and GRAVITI Results
Parakkal Deepak, Andres J Yarur, Tadakazu Hisamatsu, Rian Van Rampelbergh, Wilbert van Duijnhoven, Shashi Adsul, Darren Piscitelli, David T Rubin, Silvio Danese
This document is available on April 30 2026
Evaluation of Complete Bowel Symptomatic Remission in Patients With Moderately to Severely Active Ulcerative Colitis
Peter D.R. Higgins, Yelina Alvarez, Thomas Baker, Matthew Germinaro, Robert Fieo, Kelly Kato, Chenglong Han
This document will be available on April 30 2026
Guselkumab Efficacy on Improvements in ACR Response Components in Participants With Active Psoriatic Arthritis and Inadequate Response to One Prior TNFi
Philip J Mease, Alice B Gottlieb, Jose U Scher, Joseph F Merola, Kimberly Parnell Lafferty, Soumya D Chakravarty, Yanli Wang, Fowzia Ibrahim, Yevgeniy Krol, Stacey Fitch, Anthony Todd, Alexis Ogdie, Christopher T Ritchlin
This document is available on April 30 2026
Pregnancy Outcomes in Maternal Exposure to Guselkumab: Review of Cases Reported to the Company Global Safety Database
Uma Mahadevan, Millie Long, Mette Julsgaard, Connie Lin, Anja Geldhof, Mauricio Rosas Ballina, Hewei Li, Javier P. Gisbert, María Chaparro
This document will be available on April 30 2026
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients With Psoriatic Arthritis: Comparison of Guselkumab versus Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Philip J Mease, Jessica Walsh, Timothy P Fitzgerald, Soumya D. Chakravarty, Elizabeth Adamson, Pavithra Srinivas, Bruno Emond, Arthur Voegel, Yuxi Wang, Sinia Sareen, Helena Huang, Patrick Lefebvre, Dominic Pilon, Shikha Singla, Joseph F Merola
This document is available on April 30 2026
Safety of Guselkumab in Participants With Active Psoriatic Arthritis: Pooled Results From Four Phase 3, Randomized, Placebo-Controlled Trials
Atul Deodhar, Alexis Ogdie, Christopher T Ritchlin, Iain B McInnes, Soumya D Chakravarty, Elizabeth Adamson, Prasheen Agarwal, Tong Wang, Alice B Gottlieb, Philip J Mease
This document will be available on April 30 2026
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.